Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

You can stop looking for glitches in the Matrix—it’s finally been proven that our universe is not merely a simulation running on some powerful alien civilization’s supercomputer. An international team ...

From his earliest gaming memories playing Spyro 2 on the PlayStation, to being obsessed with the swing-out animations in Marvel's Spider-Man, Cameron has always been, and continues to be, in love with ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

Vertex Pharmaceuticals (VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically had a strong R&D pipeline and has consistently been a winner, but the ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex Pharmaceuticals said Monday that ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...

Vertex Pharmaceuticals' stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into advanced testing. Shares slid 14% to $407.30.

Abstract: Vertex-frequency analysis (VFA) is a useful technique in graph signal processing to extract the correspondence between frequencies and vertices. VFA can be calculated by the windowed graph ...